logo
RFK Jr.'s False Claims On Aluminum In Vaccines Could Lead To A Ban

RFK Jr.'s False Claims On Aluminum In Vaccines Could Lead To A Ban

Forbes4 days ago
Health and Human Services Secretary Robert F. Kennedy may soon be asking the Advisory Committee on Immunization Practices to examine aluminum ingredients in vaccines, according to Bloomberg News. Kennedy has long falsely asserted that vaccines containing aluminum salts as an adjuvant cause health problems. He has made similar claims regarding vaccines that include thimerasol as an adjuvant. In June, ACIP recommended against the use of thimerasol in influenza vaccines. Unlike thimerasol, which is only used in a small percentage of influenza vaccines, multiple types of vaccines contain aluminum. This implies that a possible decision to curb or ban its use could have far-reaching implications.
Speaking to governors on July 26th, RFK Jr. said 'we need to look at the aluminum in the vaccines to see if that has anything to do with this explosion of allergies that began in 1989, which was the year they expanded the vaccine schedule.' He specifically cited the hepatitis B jab, falsely saying that in Israel doses of hepatitis B vaccines are not given after birth (they are).
This isn't the first time Kennedy has criticized the use of aluminum in vaccines. He said on a podcast in 2024 that aluminum in vaccines is 'extremely neurotoxic.'
Aluminum salts are used in vaccines as an adjuvant to help boost a person's immune response. According to the Centers for Disease Control and Prevention, this ingredient has been used safely in vaccines for more than 70 years, initially in the 1930s, 1940s and 1950s with diphtheria and tetanus vaccines; later, in routinely recommended hepatitis, human papilloma virus, pneumococcal and meningococcal vaccines. Of note, aluminum is not used in live, weakened viral vaccines, like measles, mumps, rubella, varicella and rotavirus.
Vaccines containing aluminum salts are tested for safety and effectiveness in clinical trials before they are licensed for use in the United States, and these vaccines are continuously monitored by the CDC and Food and Drug Administration once they are approved. While at high doses, aluminum is a neurotoxin, the amount contained in vaccines is minuscule.
The thimerosal story hints at what could happen should ACIP recommend against the use of aluminum salts. Vaccine makers have long used the mercury-based preservative thimerosal to prevent microbial growth. Experts don't consider thimerosal unsafe. Yet Kennedy's new handpicked ACIP panel voted against flu shots containing thimerosal, despite lack of evidence of negative health effects. Kennedy has now signed off on the recommendation to remove thimerosal from influenza vaccines distributed in the United States. This only impacts a relatively small percentage (4%) of flu vaccines administered to Americans. On the other hand, removing aluminum would impact a much larger number of vaccines.
Aluminum is found in numerous foods and beverages, including fruits and vegetables, beer and wine, seasonings, flour, cereals, nuts, dairy products, baby formulas and honey. And besides vaccines, other health products such as antacids, buffered aspirin and antiperspirants contain aluminum. Typically, adults ingest seven to nine milligrams of aluminum daily.
Kennedy's claim that aluminum in vaccines is causing an explosion of allergies is considered misinformation by experts. Moreover, his assertion that Israel delays the hepatitis B shot is inaccurate; Israel follows World Health Organization guidelines and vaccinates newborns just like the U.S. While there has been a worldwide rise in allergies, experts don't attribute it to vaccines. It's considered a complex issue driven by environmental factors, genetics and lifestyle.
A newly published study of over one million people in Denmark found no link between aluminum and 50 chronic conditions, including autism, allergies and autoimmune diseases. The research included more than 1.2 million people in Denmark who received childhood vaccines. Researchers analyzed medical records of these individuals over a 24-year period. The catalyst for the Danish research was a widely criticized CDC-funded study, published in 2022, that suggested a link between aluminum in childhood vaccines and increased asthma risk. The study, however, didn't distinguish between aluminum from vaccines and from other sources.
Previous analyses also showed no correlation between aluminum exposure through vaccines and risks of disease. In 2000, the U.S.-based National Vaccine Program Office determined that no changes to vaccine recommendations were needed after it conducted a review. Likewise, the World Health Organization's Global Advisory Committee on Vaccine Safety evaluated studies and found no evidence of health risks that would require changes to vaccine policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...

Yahoo

timean hour ago

  • Yahoo

Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...

Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio

Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says
Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says

Yahoo

timean hour ago

  • Yahoo

Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says

Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says originally appeared on Men's Fitness. Longevity is a trending topic these days, with people turning to all kinds of products and gimmicks to try and extend their lifespan. But Biochemist Rhonda Patrick just revealed a simple, science-backed solution that could add five years to your life: omega-3's. Omega-3s are fatty acids that play a key role in brain function, heart health, and reducing inflammation throughout the body. They're found primarily in fatty fish like salmon and mackerel, and can be supplemented with fish oil and certain plant sources like flaxseed. An optimal omega-3 index is around 8 percent, but the U.S. average hovers below 5 percent. That difference could translate to a five-year increase in life expectancy."Studies have been done and it takes about on average 2 grams of omega-3 supplementation a day to go from 4 percent to 8 percent," Patrick says. "People that have the 8 percent omega-3 index have a five year increased life expectancy compared to people that have 4 percent." To raise your omega-3 index, consider supplementing with high-quality fish oil or eating fatty fish like salmon regularly. The benefits don't stop there. High omega-3 intake is also associated with better brain health, lower inflammation, reduced risk of Alzheimer's, and even protection against muscle loss. "There's studies showing that you're much less likely to get Alzheimer's disease if you have a high omega-3 index. The quality of life is better," Patrick says. One study even found that smokers with high omega-3 levels live as long as non-smokers with low omega-3 levels. "I think omega-3 has the pharmacological potential to act like drugs but the safety profile of a nutrient," Patrick This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says first appeared on Men's Fitness on Jul 10, 2025 This story was originally reported by Men's Fitness on Jul 10, 2025, where it first appeared. Solve the daily Crossword

Cardiologist Swears by 3 Everyday Supplements to Prevent One Deadly Disease
Cardiologist Swears by 3 Everyday Supplements to Prevent One Deadly Disease

Yahoo

timean hour ago

  • Yahoo

Cardiologist Swears by 3 Everyday Supplements to Prevent One Deadly Disease

Cardiologist Swears by 3 Everyday Supplements to Prevent One Deadly Disease originally appeared on Men's Fitness. Heart disease is the leading cause of death in the U.S., but certain supplements—paired with a healthy, balanced lifestyle—can help support long-term heart health, as one cardiologist shared. Dmitry Yaranov, M.D., director of the advanced heart failure program at Baptist Memorial Hospital, shared with Business Insider the three daily supplements he swears by to support his heart health. According to the CDC, 919,032 Americans died from cardiovascular disease in 2023, accounting for roughly one in every three deaths. With stats like that, Yaranov is extra mindful of his health. Here are the three supplements he endorses to reduce risk of cardiovascular disease:Omega-3 Yaranov says omega-3 has the strongest research backing for heart health, which is why he's taken it for years. Omega-3 fatty acids—particularly EPA and DHA—help lower triglycerides, reduce blood pressure, and decrease inflammation, all of which are risk factors for cardiovascular disease. It's found naturally in fatty fish like salmon, sardines, and mackerel. But Yaranov admits he doesn't eat enough of it: "I know that for sure, I'm not getting enough fresh, fatty fish in my diet," he said—so the supplements to close the gap. Magnesium Glycinate Reportedly, roughly 50 percent of Americans consume less than the Estimated Average Requirement for magnesium—making a strong case for supplementation. Low magnesium levels are linked to high blood pressure, irregular heart rhythms, and increased risk of heart attack. Magnesium glycinate is more easily absorbed, supporting muscle and nerve function. Vitamin D If you spend most of your time indoors—like Yaranov does—a vitamin D supplement might be necessary. Vitamin D is synthesized when your skin is exposed to sunlight, but modern indoor lifestyles often mean we don't get enough naturally. Vitamin D deficiency could be the risk factor for cardiovascular diseases, such as heart disease and stroke, as one 2023 study Swears by 3 Everyday Supplements to Prevent One Deadly Disease first appeared on Men's Fitness on Jul 18, 2025 This story was originally reported by Men's Fitness on Jul 18, 2025, where it first appeared.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store